13 Prostate Cancer Clinical Trials in Durham, NC (2026)

Q: How do I join a clinical trial in Durham?

Browse available studies, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you.

Recruiting Prostate Cancer Studies in Durham

NCT07144228Recruiting

Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer

This is a single center study evaluating whether a new blood test based on platelet proteins rather than plasma proteins can improve detection of prostate cancer and evaluate the degree of serious dis...

Durham, NC300 participantsDuke University

View Study Details

NCT06800313Recruiting

A Study of HLD-0915 in Patients With Metastatic Castration Resistant Prostate Cancer (mCRPC)

Assessment of the safety and efficacy of HLD-0915 as monotherapy in patients with metastatic castration resistant prostate cancer (mCRPC) that have progressed on prior systemic therapies, once a recom...

Durham, NCPHASE1190 participantsHalda Therapeutics OpCo, Inc.

View Study Details

NCT07190300Recruiting

TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)

The purpose of the study is to evaluate the safety, tolerability, and efficacy of the two different treatment combinations of tulmimetostat in participants with de novo or recurrent Metastatic Hormone...

Durham, NCPHASE1181 participantsNovartis Pharmaceuticals

View Study Details

NCT07103018Recruiting

A Clinical Study of KTX-2001 in Subjects With Metastatic Castration-Resistant Prostate Cancer (STRIKE-001)

Study K36-MCRPC-001 is the first in human clinical trial testing KTX-2001 alone and with darolutamide in men with metastatic castration-resistant prostate cancer. The study aims to assess whether the ...

Durham, NCPHASE1144 participantsK36 Therapeutics, Inc.

View Study Details

NCT06067841Recruiting

A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer

The purpose of this study is to assess the safety, tolerability, and preliminary efficacy of BMS-986460 in men with Metastatic Castration-resistant Prostate Cancer....

Durham, NCPHASE1140 participantsBristol-Myers Squibb

View Study Details

NCT05832086Recruiting

Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes

This is a Phase 2, randomized two-armed, multi-site study of 138 patients with metastatic castrate sensitive prostate adenocarcinoma. Patients will be randomized 1:1 to receive the fasting mimicking d...

Durham, NCPHASE2138 participantsStephen Freedland

View Study Details

NCT06141993Recruiting

ARCTIC: Liquid Biomarkers in the Prospective Androgen Receptor Signaling Inhibitors (ARSI) Resistance Clinical Trials

This study will follow men with metastatic castration resistant prostate cancer throughout their standard of care treatment for their disease to determine if the presence of different genes or protein...

Durham, NC120 participantsDuke University

View Study Details

NCT06022822Recruiting

Placebo-Controlled Trial of Urolithin A Supplementation in Men With Prostate Cancer Undergoing Radical Prostatectomy, URO-PRO Trial

This phase II randomized control trial assesses the effect of Urolithin A (Uro-A) supplementation compared to placebo in men with biopsy-confirmed prostate cancer undergoing radical prostatectomy (RP)...

Durham, NCPHASE290 participantsNational Cancer Institute (NCI)

View Study Details

NCT06549465Recruiting

Study Evaluating Dosimetry, Randomized Dose Optimization, Dose Escalation and Efficacy of Ac-225 Rosopatamab Tetraxetan in Participants With PSMA PET-Positive Castration-Resistant Prostate Cancer (CRPC)

This is a three-part study evaluating the safety and efficacy of a PSMA-directed radioantibody (rosopatamab tetraxetan, conjugated to either In-111 or Ac-225). Part 1 will consist of one administratio...

Durham, NCPHASE260 participantsConvergent Therapeutics

View Study Details

NCT06228053Recruiting

Study of SX-682 Plus Enzalutamide in Men With Abiraterone-Resistant Metastatic Castration Resistant Prostate Cancer

The goal of this clinical trial is to study the combination of SX-682 plus enzalutamide in men with metastatic castration resistant prostate cancer (mCRPC) who have failed abiraterone....

Durham, NCPHASE253 participantsSyntrix Biosystems, Inc.

View Study Details

NCT05011383Recruiting

High Dose Testosterone for ATM, CDK12 or CHEK2 Altered Prostate Cancers

This study will determine whether the presence of DNA repair deficiency in the form of alterations in the genes ATM, CDK12 or CHEK2 predicts for a high likelihood of responding to the use of intermitt...

Durham, NCPHASE251 participantsVA Office of Research and Development

View Study Details

NCT06457919Recruiting

A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer

The purpose of this study is to find out whether tinengotinib in combination with abiraterone acetate and prednisone or enzalutamide is a safe treatment that causes few or mild side effects in people ...

Durham, NCPHASE150 participantsMemorial Sloan Kettering Cancer Center

View Study Details

NCT07050433Recruiting

COMPASS Study for Metastatic Castration-resistant Prostate Cancer

This study is a companion to the SYNERGY-201 clinical trial (NCT06228053), which investigates SX-682 and enzalutamide in individuals with prostate cancer. Individuals must be participating in SYNERGY-...

Durham, NC48 participantsDuke University

View Study Details

About Prostate Cancer Clinical Trials in Durham

Prostate cancer develops in the prostate gland and is one of the most common cancers in men. Many prostate cancers grow slowly, but some can be aggressive. Treatment options range from active surveillance to surgery, radiation, and hormone therapy.

There are currently 13 prostate cancer clinical trials recruiting participants in Durham, NC. These studies are seeking a combined 1,565 participants. Research is being sponsored by Duke University, Halda Therapeutics OpCo, Inc., Novartis Pharmaceuticals and 8 other organizations. Clinical trial participation is free and participants receive study-related medical care at no cost.

Prostate Cancer Clinical Trials in Durham — FAQ

Are there prostate cancer clinical trials in Durham?

Yes, there are 13 prostate cancer clinical trials currently recruiting in Durham, NC. Browse the studies on this page to find one that fits.

How do I join a clinical trial in Durham?

Browse the studies listed above, click one that interests you, and complete the free eligibility form. A study coordinator at the Durham research site will contact you about next steps.

Are clinical trials in Durham free?

Yes, clinical trial participation is always free. Study-related treatment, medical tests, and doctor visits are provided at no cost. Many Durham studies also compensate for your time and travel.

What prostate cancer treatments are being tested?

The 13 active trials in Durham are testing new therapies including novel drugs, biologics, and treatment approaches for prostate cancer.

Data updated July 17, 2026 from ClinicalTrials.gov